Evaluating the potential health and economic impact of different vaccination strategies with the adult-specific 21-valent pneumococcal conjugate vaccine in adults aged ≥ 65 years in Japan
BACKGROUND: We estimated the health and economic impact of adult pneumococcal vaccination strategies in Japan, comparing the adult-specific PCV21 (aPCV21) to PCV20. RESEARCH DESIGN AND METHODS: A published Markov model simulated the epidemiology of pneumococcal disease in Japanese adults aged ≥ 65 years over a lifetime horizon using single- and multi-cohort analyses. Outcomes included cases of invasive pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (NBPP), disease-related deaths, and direct and indirect costs (2023 Japanese yen [¥]). The base case evaluated vaccination at age 65, while scenario analyses assessed expanded age-based (≥65) vaccination, coverage rates, duration of protection, and indirect protection. RESULTS: Compared to PCV20, aPCV21 prevented 35% more IPD outcomes (cases and deaths) and 33% more NBPP outcomes in the base case. Combined direct and indirect disease/death-related cost savings versus no vaccination increased from ¥3,983 million with PCV20 to ¥5,299 million with aPCV21. Expanding age-based vaccination from adults aged 65 to ≥65 years, prevented an additional 12% points of IPD outcomes and 6% points of NBPP outcomes. Across all scenario analyses, aPCV21 prevented ≥ 25% more cases and costs compared to PCV20. CONCLUSIONS: Based on scenario analyses, the use of aPCV21 in Japanese adults provides substantial health and economic benefits compared to PCV20.
Authors
- Kelly D. Johnson (ORCID: https://orcid.org/0000-0002-4275-6135)
- Atsushi Tajima (ORCID: https://orcid.org/0000-0001-9193-9934)
- Zinan Yi (ORCID: https://orcid.org/0009-0002-4997-3121)
- Peter P. Mueller (ORCID: https://orcid.org/0000-0002-5334-0362)
- Taizo Matsuki (ORCID: https://orcid.org/0000-0002-0591-4261)
- Nicole Cossrow (ORCID: https://orcid.org/0009-0006-4982-4547)
- Kelsie Cassell (ORCID: https://orcid.org/0000-0003-0369-4186)
- Kwame Owusu‐Edusei (ORCID: https://orcid.org/0000-0002-4519-2857)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- MSD K.K. (Japan) (JP)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1080/14760584.2026.2761707
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 0.00